ALK and neuroblastoma: We performed a metabolic activity screen with 14 clinically approved drugs targeting a wide range of cancer‐ and neuroblastoma‐relevant pathways, such as ALK, MAPK, and PI3K, to identify agents that can overcome VCR resistance (Fig. 1A).